Cargando…
An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042110/ https://www.ncbi.nlm.nih.gov/pubmed/33846537 http://dx.doi.org/10.1038/s42003-021-01977-7 |
_version_ | 1783678057626730496 |
---|---|
author | Hamada, Shun Nagase, Masashi Yoshizawa, Tomohiko Hagiwara, Akari Isomura, Yoshikazu Watabe, Ayako M. Ohtsuka, Toshihisa |
author_facet | Hamada, Shun Nagase, Masashi Yoshizawa, Tomohiko Hagiwara, Akari Isomura, Yoshikazu Watabe, Ayako M. Ohtsuka, Toshihisa |
author_sort | Hamada, Shun |
collection | PubMed |
description | Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminated by the spurious activation of en passant fibers that compromise the accurate interpretation of functional effects. Here, we explored the engineering of a ChR2 variant specifically localized to presynaptic axon terminals. The metabotropic glutamate receptor 2 (mGluR2) C-terminal domain fused with a proteolytic motif and axon-targeting signal (mGluR2-PA tag) localized ChR2-YFP at axon terminals without disturbing normal transmission. mGluR2-PA-tagged ChR2 evoked transmitter release in distal projection areas enabling lower levels of photostimulation. Circuit connectivity mapping in vivo with the Spike Collision Test revealed that mGluR2-PA-tagged ChR2 is useful for identifying axonal projection with significant reduction in the polysynaptic excess noise. These results suggest that the mGluR2-PA tag helps actuate trafficking to the axon terminal, thereby providing abundant possibilities for optogenetic experiments. |
format | Online Article Text |
id | pubmed-8042110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80421102021-04-28 An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping Hamada, Shun Nagase, Masashi Yoshizawa, Tomohiko Hagiwara, Akari Isomura, Yoshikazu Watabe, Ayako M. Ohtsuka, Toshihisa Commun Biol Article Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminated by the spurious activation of en passant fibers that compromise the accurate interpretation of functional effects. Here, we explored the engineering of a ChR2 variant specifically localized to presynaptic axon terminals. The metabotropic glutamate receptor 2 (mGluR2) C-terminal domain fused with a proteolytic motif and axon-targeting signal (mGluR2-PA tag) localized ChR2-YFP at axon terminals without disturbing normal transmission. mGluR2-PA-tagged ChR2 evoked transmitter release in distal projection areas enabling lower levels of photostimulation. Circuit connectivity mapping in vivo with the Spike Collision Test revealed that mGluR2-PA-tagged ChR2 is useful for identifying axonal projection with significant reduction in the polysynaptic excess noise. These results suggest that the mGluR2-PA tag helps actuate trafficking to the axon terminal, thereby providing abundant possibilities for optogenetic experiments. Nature Publishing Group UK 2021-04-12 /pmc/articles/PMC8042110/ /pubmed/33846537 http://dx.doi.org/10.1038/s42003-021-01977-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hamada, Shun Nagase, Masashi Yoshizawa, Tomohiko Hagiwara, Akari Isomura, Yoshikazu Watabe, Ayako M. Ohtsuka, Toshihisa An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title | An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title_full | An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title_fullStr | An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title_full_unstemmed | An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title_short | An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
title_sort | engineered channelrhodopsin optimized for axon terminal activation and circuit mapping |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042110/ https://www.ncbi.nlm.nih.gov/pubmed/33846537 http://dx.doi.org/10.1038/s42003-021-01977-7 |
work_keys_str_mv | AT hamadashun anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT nagasemasashi anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT yoshizawatomohiko anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT hagiwaraakari anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT isomurayoshikazu anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT watabeayakom anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT ohtsukatoshihisa anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT hamadashun engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT nagasemasashi engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT yoshizawatomohiko engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT hagiwaraakari engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT isomurayoshikazu engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT watabeayakom engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping AT ohtsukatoshihisa engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping |